ViaCyte's potential diabetes 'cure' gets another $6m to move into human trials
This article was originally published in Scrip
With another $6 million to fund ViaCyte's stem cell-based diabetes product, which the San Diego-based company has said could reduce or eliminate the need for pharmaceutical insulin, the Juvenile Diabetes Research Foundation (JDRF) has contributed $7 million and the California Institute for Regenerative Medicine (CIRM) has financed nearly $40 million in preclinical work for the VC-01 therapeutic and device combination product.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.